Form4insider filings, from the source

SEC Form 4 · accession 0001193805-15-002087

Vanda Pharmaceuticals Inc. · VNDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owners
DEERFIELD MANAGEMENT CO
10% Owner · Other
Deerfield Mgmt L.P.
10% Owner · Other
DEERFIELD PARTNERS, LP
10% Owner · Other
James E Flynn
10% Owner · Other
Period of report
Dec 9, 2015
Accepted (ET)
Dec 11, 2015 · 6:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F4,F5Dec 9, 2015P229,833$8.211A2,003,992IThrough Deerfield Partners, L.P.
Common StockF1,F4,F5Dec 9, 2015P292,515$8.211A2,550,535IThrough Deerfield International Master Fund, L.P.
Common StockF1,F4,F5Dec 9, 2015P213,358$8.211A965,336IThrough Deerfield Special Situations Fund, L.P.
Common StockF4,F5Dec 9, 2015P12,395$9.00A2,016,387IThrough Deerfield Partners, L.P.
Common StockF4,F5Dec 9, 2015P15,775$9.00A2,566,310IThrough Deerfield International Master Fund, L.P.
Common StockF4,F5Dec 9, 2015P11,506$9.00A976,842IThrough Deerfield Special Situations Fund, L.P.
Common StockF2,F4,F5Dec 10, 2015P40,997$8.5902A2,057,384IThrough Deerfield Partners, L.P.
Common StockF2,F4,F5Dec 10, 2015P32,211$8.5902A2,598,521IThrough Deerfield International Master Fund, L.P.
Common StockF2,F4,F5Dec 10, 2015P29,902$8.5902A1,006,744IThrough Deerfield Special Situations Fund, L.P.
Common StockF3,F4,F5Dec 11, 2015P100,864$8.6089A2,158,248ITThrough Deerfield Partners, L.P.
Common StockF3,F4,F5Dec 11, 2015P128,374$8.6089A2,726,895IThrough Deerfield International Master Fund, L.P.
Common StockF3,F4,F5Dec 11, 2015P93,634$8.6089A1,100,378IThrough Deerfield Special Situations Fund, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Avalanche Biotechnologies, Inc. filed with the Securities and Exchange Commission on July 30, 2014 by Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn